This is the request to the US Food and Drug Administration (FDA) to administer an investigational new drug to humans.
The firm and Corin is being featured on 'CEO Clips' airing on Bloomberg Television from July 10 to July 14.
"We’ll probably be filing two IND’s by the end of this year so a tremendous amount of development ahead, some really great catalysts and we should have an NDA or a new drug application by the end of next year which will be phenomenal for a very young company," he told the interview.
The group, which has four products in the pipeline, is about to launch commercially its 'revenue -ready' and FDA approved Strontium Chloride (SR89) product for bone cancer pain, planned for this year, which will be a big milestone.
Corin added: "We'll probably be filing two IND’s one for the autism spectrum disorder the rare pediatric disease by the end of this year and fairly closely behind that I would expect the liver cancer drug indeed to be filed.
"Both of those going into the clinic hopefully in early 2018 and the glaucoma drug will also be moved through its pre IND clinical program and into the clinic hopefully or IND enabling studies early in 2019.
"So, a tremendous amount of development ahead some really great catalyst and we should have an NDA or a new drug application by the end of next year..."
The idea behind the Q BioMed model is that there would be consistent milestone turnover and catalyst events happening throughout the development pipeline and give shareholders something interesting to look forward to on a continuous basis.